Webinar: Clinical Readiness – Practical and Innovative Solutions for AAV Development and Manufacturing
Date: Tuesday, June 23
Time: 9:00AM ET
What are the current challenges and future promises of adeno-associated virus (AAV), lentivirus, and lipid nanoparticles in gene therapies? George Buchman, Ph.D., Vice President of Preclinical & Process Development at Catalent Gene Therapy, will discuss specific case studies for neuromuscular degenerative indications, AAV technology and manufacturing, strategies for navigating the current regulatory environments in the U.S. and Europe, and much more in this upcoming webinar.
George Buchman, PhD
VP, Preclinical & Process Development, Catalent Gene Therapy